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Available online 4 October 2012A commonly carried C677T polymorphism in a folate-related gene, MTHFR, is associated with higher plasma
homocysteine, a well-known mediator of neuronal damage and brain atrophy.
As homocysteine promotes brain atrophy, we set out to discover whether people carrying the C677T MTHFR
polymorphism which increases homocysteine, might also show systematic differences in brain structure.
Using tensor-based morphometry, we tested this association in 359 elderly Caucasian subjects with mild cogni-
tive impairment (MCI) (mean age: 75±7.1 years) scannedwith brainMRI and genotyped as part of Alzheimer's
Disease Neuroimaging Initiative. We carried out a replication study in an independent, non-overlapping sample
of 51 elderly Caucasian subjects withMCI (mean age: 76±5.5 years), scannedwith brainMRI and genotyped for
MTHFR, as part of the Cardiovascular Health Study. At each voxel in the brain, we tested to see where regional
volume differences were associated with carrying one or moreMTHFR ‘T’ alleles.
In ADNI subjects, carriers of theMTHFR risk allele had detectable brain volume deficits, in the white matter, of
up to 2–8% per risk T allele locally at baseline and showed accelerated brain atrophy of 0.5–1.5% per T allele at
1 year follow-up, after adjusting for age and sex. We replicated these brain volume deficits of up to 5–12% per
MTHFR T allele in the independent cohort of CHS subjects.
As expected, the associations weakened after controlling for homocysteine levels, which the risk gene affects.
The MTHFR risk variant may thus promote brain atrophy by elevating homocysteine levels.
This study aims to investigate the spatially detailed effects of thisMTHFR polymorphism on brain structure in 3D,
pointing to a causal pathway thatmay promote homocysteine-mediated brain atrophy in elderly peoplewithMCI.
© 2012 The Authors. Published by Elsevier Inc. All rights reserved.terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any
edited.
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As life expectancy increases, a rapidly increasing number of people
worldwide are affected by degenerative brain disorders (Mattson et al.,
2002). It is vital to identify factors that influence neurodegeneration to
promote successful brain aging through genetic (germline gene thera-
py) and environmental (dietary and behavioral) modifications.
Several new factors have recently been discovered that promote
or resist brain atrophy in the elderly. Among those that could in prin-
ciple be influenced by pharmaceutical or even dietary interventions
are factors in the folate/homocysteine pathway (Smith et al., 2010).
Homocysteine is an amino acid measurable in the blood. Genetic
variations explain 45–60% of the variance in plasma homocysteine
levels in normal adults (Bathum et al., 2007; Siva et al., 2007).
A commonly carried genetic variant – a single nucleotide poly-
morphism (SNP) (C677T locus; rs1801133) in the well-known candi-
date gene methylenenetetrahydrofolate reductase (MTHFR) on
chromosome 1 – explains a fair proportion (24–53%) of this genetic
variance (Bathum et al., 2007). The C677T change in the MTHFR
gene replaces cytosine with thymine at base position 677. Carriers
of the T allele have a less active MTHFR enzyme and higher homocys-
teine levels, especially when their folate levels are low. This has been
consistently shown in several genome-wide association studies
(Hazra et al., 2009; Lange et al., 2010; Mälarstig et al., 2009; Pare et
al., 2009; Raz et al., 2011; Tanaka et al., 2009). The MTHFR C677T ‘T’
allele has also been shown, albeit inconsistently, to be associated
with white matter hyperintensities (de Lau et al., 2010; Hong et al.,
2009; Kohara et al., 2003; Raz et al., 2011; Watfa et al., 2010).
This risk variant is widely prevalent in the United States: 40% and
11% of the non-Hispanic white population carry one or two risk alleles,
respectively (Yu et al., 2010); theminor allele frequency is reported to
be 31% in Western and Central Europeans (Altshuler et al., 2010).
Homocysteine is toxic to neurons via direct DNA damage and
excitotoxicity, inducing apoptosis (Sachdev, 2005). High homocyste-
ine levels have also been associated with brain atrophy in the elderly.
Recently, we have shown that higher plasma homocysteine levels are
associated with regional brain volume deficits in elderly Caucasian
people, more specifically in people with mild cognitive impairment
(MCI) (Rajagopalan et al., 2011).
If homocysteine is associated with brain atrophy in elderly people
with mild cognitive impairment, then carriers of the MTHFR C677T
risk polymorphism may show detectable differences in brain struc-
ture on MRI. By showing that brain structure is affected not just by
homocysteine levels, but also by a commonly carried genetic variant
that in turn elevates plasma homocysteine levels, a causal pathway
to brain atrophy could begin to be elucidated — revealing brain sys-
tems affected, and the extent of their deficits in risk variant carriers
(Fig. 1).
We hypothesized that we would find brain regions with structural
deficits in subjects carrying theMTHFR risk allele. This study aims to in-
vestigate the spatially detailed effects of the homocysteine-associated
MTHFR risk ‘T’ allele on brain structure in 3D.Fig. 1. Established associations are shown (solid lines) based on the literature.We tested
whether carriers of the MTHFR risk allele would show detectable differences on brain
MRI (dotted lines).Materials and methods
Subjects
Subjects were selected from two separate cohorts: the Alzheimer's
Disease Neuroimaging Initiative (ADNI) (Table 1) and the Cardiovas-
cular Health Study (CHS) (Table 2).
Alzheimer's Disease Neuroimaging Initiative (ADNI)
The ADNI was launched in 2004 as a 5-year public–private part-
nership to assess biomarkers of Alzheimer's disease (Mueller et al.,
2005a,b). The first phase of ADNI (sometimes known as “ADNI1”)
assessed 842 subjects in total — 200 with Alzheimer's disease (AD),
410 with MCI and 232 cognitively normal; mean age: 75·3±
6·8 years) at baseline who received a 1.5 Tesla brain MRI scan at
one of 58 sites across North America and were genotyped as part of
the study.
We considered the MCI group for our primary hypothesis, as
MCI was the largest diagnostically homogeneous group in ADNI.
In the MCI group, regional brain volumes showed strongest and
most highly significant associations with homocysteine levels in
our earlier work (Rajagopalan et al., 2011). In ADNI, almost the en-
tire cohort was Caucasian; we therefore assessed only Caucasian
(non-Hispanic) elderly subjects with MCI (n=359) (Table 1) to
avoid population stratification effects which can lead to spurious
genetic associations (Lander and Schork, 1994). Of the 359 sub-
jects, 171 had a history of hypertension, 8 had a history of stroke
at baseline, 58 subjects had a history of coronary artery disease,
25 subjects had non-insulin dependent diabetes and 1 subject
had insulin-dependent diabetes. We followed up 307 of these 359
MCI subjects after a 12-month interval, to test MTHFR polymor-
phism associations with the longitudinal rate of brain atrophy, es-
timated from the baseline and 1-year follow-up scans.
A second, purely exploratory, analysis was undertaken to test the
associations of the MTHFR SNP in the AD and the cognitively normal
control groups.
A post-hoc analysis was carried out using baseline and one-year
bilateral cerebral white matter volumes (cc) based on the imaging
data from the ADNI database processed by the UCSF team, who
performed volumetric segmentations with the FreeSurfer image anal-
ysis suite (http://surfer.nmr.mgh.harvard.edu/). Volumes for 355 of
the 359 Caucasian subjects at baseline and 303 of the 307 Caucasian
subjects at one-year were reported to have passed quality control
and were therefore used in the analysis.
The study was conducted according to the Good Clinical Practice
guidelines, the Declaration of Helsinki, and US 21 CFR Part 50 — Protec-
tion of Human Subjects, and Part 56 — Institutional Review Boards. All
participants gave written informed consent. Inclusion and exclusion
criteria are detailed in the ADNI protocol (Mueller et al., 2005a). All
data are publicly available (http://www.loni.ucla.edu/ADNI/).
The Cardiovascular Health Study (CHS)
We opted to test the MTHFR SNP in CHS subjects diagnosed with
MCI, to replicate the associations found in the ADNI MCI group. CHS
is an independently assessed cohort, and it was also analyzed here
to determine whether the findings from ADNI might generalize to a
larger population.
The CHS-CS (Cognition Study) was designed to determine the inci-
dence of dementia and mild cognitive impairment (MCI) in a large co-
hort of subjects first assessed in 1998 — subjects were recruited from a
Medicare database andwere eligible if theywere over age 65, ambulato-
ry, and non-institutionalized. In 1998–1999, a subgroup of subjects had
been identified as normal or MCI in 1991–1994. By 1999, 456 of these
subjects had completed neurological and neuropsychological examina-
tions and were scanned with 3-dimensional volumetric brain MRI.
Table 1
Shown here are the ADNI MCI cohort's demographic and clinical characteristics, split by MTHFR (rs1801133) genotype.
Mean (standard error) CC (homozygous non-risk genotype) CT (heterozygous risk genotype) TT (homozygous risk genotype) ANOVA test results⁎
Sample size (n)
(M — males, F — females)
149 (92 M, 57 F) 157 (103 M, 54 F) 53 (36 M, 17 F) χ2 2=0.8, p=0.66
Age (years) 75 (0.5) 75 (0.5) 75 (0.9) F2, 356=0.04, p=0.96
BMIα (kg/m2) 25.8 (0.3) 26.5 (0.05) 25.7 (0.3) F2, 344=1.26, p=0.28
Systolic BPβ (mm Hg) 135.8 (1.1) 135.4 (1.2) 133.1 (1.9) F2, 256=0.44, p=0.64
Diastolic BPβ (mm Hg) 74.8 (0.6) 74.7 (0.7) 73.1 (1.0) F2, 356=0.71, p=0.49
White matter hyperintensity 0.8 (0.4) 0.9 (0.2) 1.0 (0.2) F2, 355=0.18, p=0.83
Homocysteineγ (μmol/L) 10.2 (0.2) 10.4 (0.2) 11.7 (0.05) F2, 352=10.4, pb0.0001⁎
MMSEδ 27.0 (0.2) 27.0 (0.2) 27.5 (0.3) F2, 356=2.18, p=0.11
Global CDRε 1.6 (0.2) 1.6 (0.1) 1.5 (0.2) F2, 356=0.17, p=0.85
APOE ε4 (0,1,2) 67, 68, 14 77, 56, 24 29, 19, 5 χ2 2=2.24, p=0.33
⁎ ANOVA tests were conducted to see if the mean clinical measure differed significantly across the genotype groups.
α Body mass index.
β Blood pressure.
γ Baseline morning fasting plasma levels.
δ Mini-mental status examination (maximum score: 30).
ε Clinical dementia rating.
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al., 1991; Tell et al., 1993). T1-weighted brain MRI scans from 1998 to
1999 were analyzed from 97 elderly subjects diagnosed with MCI in
the Cardiovascular Health Study (CHS) (mean age: 76.5±5.5 years).
As for ADNI study, we considered only a subset of 83 MCI Caucasian
subjects to reduce population stratification effects. Of those 83 sub-
jects, 51 had been genotyped for theMTHFR SNP. 15 of these subjects
had data on homocysteine levels in the blood, 50 had data on folate
levels, and 47 had been genotyped for ApoE4 status (Table 2).
MRI acquisition, calibration, and correction
ADNI baseline
Subjects were scanned at multiple ADNI sites according to a stan-
dardized protocol developed after a major effort to evaluate 3D
T1-weighted sequences for morphometric analyses (Jack et al.,
2008; Leow et al., 2006). See Supplementary materials for a detailed
description.
12-months follow-up
307 Caucasian subjects with MCI were scanned and analyzed at
baseline (0 months), and at around one-year after their baseline
scans. The follow-up slightly varied among the 307 subjects;
10 months for 1 subject, 12 months for 59 subjects, 13 months for
176 subjects, 14 months for 52 subjects, 15 months for 12 subjects
and 16 months for 7 subjects. In these 307 subjects, we tested the asso-
ciations of theMTHFR SNPwith regional rate of brain atrophy over time
computed across the 1-year interval. Rates of brain atrophy wereTable 2
Shown here are the CHS MCI cohort's demographic and clinical characteristics, split by rs18
Mean (standard error) CC (homozygous non-risk genotype) CT (heterozy
Sample size (n)
(M — males, F — females)
16
(8 M, 8 F)
29
(11 M, 18 F)
Age (years) 74 (1.4) 77 (1.0)
BMIα (kg/m2) 25.3 (1.4) 25.0 (1.0)
Systolic BPβ (mm Hg) 128.7 (3.7) 138.3 (3.4)
Diastolic BPβ (mm Hg) 65.4 (1.7) 69.3 (1.4)
Homocysteineγ (μmol/L) 10.1 (0.2) 11.5 (0.2)
Folateδ 534.7 (91.3) 537.1 (54.7)
⁎ ANOVA and chi-squared tests were conducted to see if the mean clinical measure diffe
α Body mass index.
β Blood pressure.
γ Plasma homocysteine levels.
δ Folate levels.
ε Only 1 subject had data.computed with an inverse-consistent method, described previously
(Leow et al., 2006).
CHS
All CHSMRI data used in this studywere acquired at the University
of Pittsburgh Medical Center (UPMC) Magnetic Resonance Research
Center using a 1.5 T GE Signa scanner (GE Medical Systems, Milwau-
kee,Wisconsin, LX Version). A 3D volumetric spoiled gradient recalled
acquisition (SPGR) sequence was obtained covering the whole brain
(TE/TR=5/25 ms, flip angle=40°, number of excitations (NEX)=1,
slice thickness=1.5 mm/0 mm interslice gap). Images were acquired
with an in-plane acquisition matrix of 256×256×124 image ele-
ments, 250×250 mm field of view, and an in-plane voxel size of
0.98 mm3.
Tensor-based morphometry (TBM) and 3D Jacobian maps in ADNI and
CHS
For each cohort, T1-weighted structural brain MRI scans were ana-
lyzed using a standard protocol (Hua et al., 2008b) and an average
brain template was constructed using brain MRI scans from 40 cogni-
tively healthy elderly individuals to enable automated image registra-
tion, reduce statistical bias and to make it easier to detect statistically
significant effects (Hua et al., 2008a,b). The two customized, study
specific, minimal deformation templates (MDT) were created from
the baseline MRI scans of 40 cognitively healthy elderly subjects for
ADNI and CHS cohorts respectively. The MDTs therefore represent
the healthy population average for each cohort respectively.01133 genotype.
gous risk genotype) TT (homozygous risk genotype) ANOVA test results⁎
6
(1 M, 5F)
χ2 2=1.0, p=0.37
73 (1.9) F2, 51=1.9, p=0.16
26.2 (1.1) F2, 44=0.1, p=0.89
133.3 (3.2) F2, 51=1.5, p=0.23
67.1 (6.0) F2, 51=0.9, p=0.41
6.3ε F2, 15=0.76, p=0.49
372.7 (49.3) F2, 50=0.6, p=0.53
red significantly across the genotype groups.
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plate for each cohort to share a common coordinate system. For each
subject, the local expansion factor of the 3D elastic warping trans-
form, calculated as the determinant of the Jacobian matrix of the de-
formation, was plotted (Leow et al., 2005) to show relative volume
differences between each individual and the common template, and
reveal areas of structural volume deficits, or expansions, relative to
the healthy population average.
TBM was also applied to the longitudinal ADNI dataset by using a
nonlinear registration algorithm to match 3D baseline structural MR
images with follow-up images acquired 12 months later as explained
in our earlier work (Leow et al., 2009).
DNA isolation and genotyping
ADNI
For the ADNI cohort, DNA extracted from peripheral B lympho-
cytes was analyzed on Human610- Quad BeadChip (Illumina). See
Supplementary materials for a detailed description.
CHS
For the CHS cohort, DNA extracted from peripheral leukocytes was
used to determine MTHFR C677T genotype, as previously described
(Frosst et al., 1995; Longstreth et al., 2004).
Testing associations of the MTHFR risk allele with brain structure
To test our primary hypothesis, associations between MTHFR ge-
notype and regional brain structure were examined in the following
groups — 1) ADNI subjects diagnosed with MCI at baseline, 2) ADNI
subjects diagnosed with MCI 1 year after their baseline scan, and
3) CHS subjects diagnosed with MCI at baseline (for the replication
study).
A secondary exploratory analysis was carried out to test for any
associations of the MTHFR variant with brain structure in the ADNI
subjects diagnosed with AD (n=173) and in normal healthy controls
(n=206), individually, at baseline.
In each group of subjects, a multiple regression was carried out at
each voxel, to test for the additive effect of carryingMTHFR risk alleles,
controlling for age and sex, as in Eq. (1):
y ¼ β0 þ βMTHFRMTHFRþ βAgeAgeþ βSexSexþ ε ð1Þ
Here the dependent variable, y, is a vector representing the deter-
minant of the Jacobian matrix of deformation (which represents brain
tissue deficit or excess relative to the average brain template) at a
particular voxel. The independent measure, MTHFR, is a vector
whose components are the integers 0, 1 or 2 across subjects. Age
and Sex are vectors representing the age and sex of each subject,
and ε is an error term. The regression model was fitted at each
voxel to localize the evidence of association between the MTHFR
risk allele and structural differences across the entire brain after
adjusting for age and sex.
Homocysteine and ApoE4 genotype were also independently con-
trolled for in the regressions to rule out any confounding effect. The
same regression analysis was repeated for the CHS MCI group of sub-
jects. As folate levels in the blood were available for the CHS cohort
unlike for ADNI, the regression model was fitted at each voxel across
the brain, with and without adjusting for homocysteine, folate, and
ApoE4 levels, in addition to age and sex.
A post-hoc analysis regressing bilateral cerebral white matter vol-
umes (cc) againstMTHFR risk alleles was also carried out in ADNI sub-
jects, after adjusting for age and sex, using the Stata software
(StataCorp, 2011, College Station, Texas).Correcting for multiple statistical comparisons
Significance maps for the above regressions were corrected for
multiple comparisons across voxels in the brain using the standard
false discovery rate (FDR) method (Benjamini and Hochberg, 1995).
We used a standard FDR correction for multiple statistical compari-
sons across all voxels in the cerebral cortex region excluding the
brain stem, at the conventionally accepted level of q=0.05. This
means that only 5% of the voxels shown in the thresholded statistical
maps are expected to be false positives. The critical p-value is
reported, which represents the highest p-value threshold for which
only 5% of the surviving voxels are expected to be false positives.
Note that the critical p-value threshold for the map is generally larger
when standardized effect sizes are larger.
Results
The genotype groups (T/T, C/T, and C/C) did not differ in any de-
mographic or clinical characteristics, for the ADNI (Table 1) and CHS
(Table 2) cohorts, respectively. 14.1% subjects were homozygous
and 43.4% were heterozygous for the MTHFR risk ‘T’ allele in the full
ADNI cohort. In the ADNI MCI cohort, 14.8% subjects were homozy-
gous and 43.7% heterozygous carriers of the risk T allele. In the CHS
subjects diagnosed with MCI, 11.8% subjects were homozygous and
56.8% heterozygous carriers of the MTHFR risk T allele.
The three main findings from this study include significant associa-
tions of the MTHFR risk ‘T’ allele with (i) cross-sectional brain volume
deficits in the bilateral periventricular fronto-parietal white matter in
ADNI MCI subjects at baseline, (ii) longitudinal annual brain atrophy in
the periventricular parietal white matter in ADNI MCI subjects at
12 month follow-up, and (iii) cross-sectional posterior parieto-occipital
white matter deficits in baseline CHS MCI subjects.
Regression beta coefficient maps corrected for FDR are shown in
Figs. 2 and 3 (upper panel) and 4, representing an estimate of the av-
erage percent brain tissue change for each unit change in the covari-
ate studied. Images are in radiological convention (left side of the
brain is shown on the right) and are displayed over the MDT. Warmer
colors (orange and red) represent regions where each unit increase in
the number of risk alleles is associated with a reduction in brain tis-
sue. There are small regions of cooler colors (blue) in the CSF regions
in the maps possibly due to partial volume effects (Hua et al., 2008a).
Graphs for the post-hoc analysis depicting the associations be-
tween bilateral cerebral white matter volumes and MTHFR risk allele
in ADNI subjects, are shown in Figs. 2 and 3 (lower panel).
MTHFR and ADNI baseline (cross-sectional) brain volumes
The additive effect of the risk ‘T’ allele was associated with signif-
icant regional brain volume deficits in white matter brain regions in
the MCI group. Here the structural differences in the brain were sig-
nificantly related to carrying the risk allele of the MTHFR gene after
adjusting for age and sex (FDR critical p-value=0.00043, controlling
the standard FDR at the 5% level). In the significantly associated re-
gions, average brain volume deficits of up to 6% per risk-conferring
‘T’ allele were found, bilaterally in the periventricular fronto-parietal
white matter, relative to the MDT. Fig. 2 (upper panel) shows beta
maps representing MTHFR associations after adjusting for age and
sex and corrected for FDR.
To rule out spurious associations due to ApoE4, we also controlled
for the presence of ApoE4 alleles, even after which the MTHFR risk al-
lele dose continued to show significant associations (FDR critical
p-value=0.0004 at q=0.05). Wealso foundno significant interactions
between ApoE4 and MTHFR risk alleles on brain volumes. Further, the
ApoE4 alleles are known to be associated with atrophy in bilateral tem-
poral regions and expansion in the occipital horn of the lateral ventricle
Fig. 2. 3D beta-coefficients maps show areas of significant volume deficits of up to 6% associated with a unit increase in carrying the MTHFR risk allele, with respect to the average
template, in baseline ADNI subjects with mild cognitive impairment. Slices demonstrating the effects are depicted in the figure.
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white matter regions found to be associated with theMTHFR risk allele.
When controlling for homocysteine levels, the associationwas found
to be significant (FDR critical p-value=0.00038 at q=0.05) but this
effect was based on only a few scattered voxels and is not shown here.
In a post-hoc analysis with cerebral white matter volumes at base-
line, we found MTHFR risk T allele to be significantly associated with
left (p=0.02) and right (p=0.046) cerebral white matter volumes
(Fig. 2 (lower panel)).
White matter hyperintensities and MTHFR risk allele
We did not find any significant associations of MTHFR risk allele
with white matter hyperintensities (p-value=0.54).
Secondary analyses in AD and control groups in ADNI
MTHFR polymorphism effects were not detectable in ADNI's small
diagnostic subgroups of subjects with AD (n=173) and the normal
healthy controls (n=206). Per ADNI's design, each of the non-MCI
groups was considerably smaller than the MCI group (n=359);
ADNI deliberately scanned around twice as many MCI subjects as
AD patients and controls. In our prior work (Rajagopalan et al.,
2011), we found homocysteine effects were associated with brain
volumes in MCI (n=356 subjects) but not in the considerably smaller
subgroups of AD patients (n=173) and normals (n=203). In the
case of homocysteine effects, we attributed it to the smaller sample
sizes, as it is somewhat unlikely that a gene effect is operating in
MCI but not in people who are less or more ill. Here, in much the
same way as the homocysteine effect, the MTHFR gene effect was
picked up in the ADNI MCI group only – the largest subgroup – butnot the two smaller subgroups (AD and controls from ADNI). Al-
though it is tempting to think that sample sizes were too small to de-
tect the effect reliably, there was a striking replication in the much
smaller CHS cohort of just 51 subjects. Two interpretations are plau-
sible: first is that there really is an effect in the CHS controls but not
ADNI, or that the effect is stronger in CHS than in ADNI, or second
that the effect is truly there all the time, but some methodological
issue made it less easy to pick up in the ADNI controls. As noted in
our prior studies of obesity in CHS and ADNI (Ho et al., 2010), the
CHS cohort tends to have a higher prevalence of vascular disease
and ApoE4 genotypes than ADNI, and there are demographic differ-
ences too. Perhaps the most nuanced explanation is that the gene ef-
fect could be operating in some cohorts but not in others, and in some
cohorts its effects may change with time; these second-order effects
will be explorable in future in much larger sample sizes (e.g., via
the Enigma Consortium; http://enigma.loni.ucla.edu). We also note
that in the cohorts where the gene effect was detected, the pattern
of findings for the genetic association is similar to the homocysteine
associations with brain volumes in our earlier work (Rajagopalan
et al., 2011) and probably also explains the effects ofMTHFR risk allele
on brain volumes in these subjects.
MTHFR and the (longitudinal) rate of brain atrophy (at 1-year
follow-up)
We also assessed brain structure in the 307 Caucasian ADNI MCI
subjects after 12 months, and found similar statistically significant
associations of the MTHFR C677T risk allele with the annual rate of
brain volume atrophy, after adjusting for age and sex (FDR critical
Fig. 3. 3D beta-coefficient maps show areas with significantly accelerated brain atrophy of up to 1.5% at 12 months follow-up, associated with a unit increase in carrying theMTHFR
risk allele, in the same ADNI subjects with mild cognitive impairment.
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The risk allele of the MTHFR SNP was associated with a significantly
greater rate of progressive atrophy of up to 1.5% per year per ‘T’ risk
allele, in the right side periventricular parietal white matter, relative
to the MDT. Fig. 3 (upper panel) shows beta maps for regional
MTHFR associations after adjusting for age and sex and corrected for
FDR.
In a post-hoc analysis with cerebral white matter volumes at
12 months, as expected, we found MTHFR risk T allele to be signifi-
cantly associated with left (p=0.001) and right (p=0.005) cerebral
white matter volumes (Fig. 3 (lower panel)).
We controlled for the presence of ApoE4 alleles, and carriers of the
MTHFR risk alleles still showed accelerated brain atrophy of up to 1.5%
(FDR critical p-value=0.0004 at q=0.05) in the same regions. There
were no significant interactions between ApoE4 and MTHFR risk al-
leles on brain volumes.
As expected from the known mechanism of the gene (it in-
creases homocysteine levels), the associations weakened consider-
ably when controlled for homocysteine. This is exactly as would be
expected, if the allele effect may be partially mediated by homocys-
teine levels.Replication study: CHS MCI subjects — MTHFR and baseline brain
volumes
To replicate our SNP association finding, we carried out a similar
analysis in the MCI subjects from the CHS dataset. We found signifi-
cant associations between the MTHFR risk alleles and brain structureafter controlling for age and sex (FDR critical p-value=0.00043 con-
trolled the standard FDR at the 5% level). Fig. 4 shows beta maps
depicting MTHFR associations after adjusting for age and sex and
corrected for FDR. This homocysteine-associated risk allele is associ-
ated with posterior parieto-occipital white matter deficits of up to
12% per risk T allele, relative to the MDT in this group.
The associations ofMTHFR risk allele with brain volumes remained
significant after adjusting for ApoE4 genotype (n=47) in addition to
age and sex (FDR critical p-value=0.0004 controlled the standard
FDR at the 5% level).
The associations ofMTHFR risk allele with brain volumes remained
significant after controlling for folate levels in the blood (n=50) in
addition to controlling for age and sex (FDR critical p-value=
0.0004 controlled the standard FDR at the 5% level). As expected,
the associations were no longer significant when controlled for plas-
ma homocysteine levels, which the gene also affects.Discussion
This is a novel study aimed to discover characteristic voxel-wise
patterns of brain atrophy associated with carrying the commonly
prevalentMTHFR C677T gene variant, in 3D.
We found that a very commonly carried variant in the MTHFR
gene, which is associated with high homocysteine levels in the
blood, is significantly associated with brain structure variation, in par-
ticular with lower regional brain volumes, in subjects with MCI in
both the ADNI and CHS cohorts. As these cohorts were independently
collected and assessed, the results strongly corroborate our findings.
Fig. 4. 3D beta-coefficients maps show areas of significant volumes deficits of up to 12% associated with a unit increase in carrying theMTHFR risk allele, with respect to the average
template, in baseline CHS subjects with mild cognitive impairment.
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(a) carrying MTHFR risk alleles was associated with having
smaller brain volumes in MCI subjects from the ADNI cohort
(Fig. 2); (b) carryingMTHFR risk alleles was associated with an accel-
erated rate of regional brain atrophy (Fig. 3) in the sameMCI subjects
from the ADNI cohort followed up after 12 months; (c) the MTHFR
associations with lower regional brain volumes were replicated in
an independent set of subjects with mild cognitive impairment
from the CHS cohort (Fig. 4); (d) the regions of associations were
not influenced by carrying ApoE4 alleles in either cohort; (e) folate
levels were controlled for in the CHS study and did not affect the re-
sults, so the MTHFR SNP effect on brain volumes was not dependent
on the folate levels; (f) plasma homocysteine levels possibly mediate
the effect: adjusting for homocysteine, as expected, weakens the as-
sociations of the MTHFR risk alleles with brain volumes in both
cohorts.
The affected periventricular fronto-parietal white matter (Figs. 2
and 3) in ADNI and parieto-occipital white matter brain regions in
CHS (Fig. 4) were identified as associated with homocysteine levels
in our prior work on ADNI MCI subjects (Rajagopalan et al., 2011).
These are regions in which white matter hyperintensities (associated
with vascular infarcts) are most commonly detected in elderly indi-
viduals (Enzinger et al., 2006). However, the associations with
white matter hyperintensities were not significant in our subjects.
This is quite interesting in itself. It could either be that theWMHmea-
sure used in ADNI is fairly noisy — as it depends to some extent on
thresholding the intensities of the scans to pick up what can some-
times be a very diffuse effect. Or it may be that the very subtle interval
changes in brain volume are more precisely quantified by methods
such as TBM, and the precision in the measures makes it easier to
pick up a correlation with other pertinent biomarkers. There is
some evidence in the latter direction, as drug trials using WMH
volumes as an outcome measure sometimes need very large sample
sizes, at least relative to measures of volumetric atrophy, which are
easier to measure precisely.
It is somewhat disappointing that the brain regions showing asso-
ciations with the MTHFR allele did not overlap in the ADNI and the
CHS datasets after statistical thresholding, although the allele effects
are likely more pervasive than the regions that survive thresholding.
The CHS MCI cohort tended to show more posterior periventricular
deficits when compared to the ADNI MCI cohort that showed in the
fronto-parietal region, after adjusting for age and sex in the regres-
sion models. Also, the MTHFR risk allele associated brain volume def-
icits were somewhat stronger in the CHS (up to 12%; Fig. 4) than in
ADNI (up to 6%; Fig. 2). These findings may reflect differences in thedemographics of the two cohorts; the subtypes of MCI subjects in
the ADNI (includes only amnestic MCI) is somewhat different from
the CHS (includes probable and possible amnestic MCI). Effects of
MCI subtypes may influence the strength and location of correlations
between brain structure and the MTHFR risk allele. Also, as we used
FDR to assess effects in the brain, we did not expect a strong congru-
ence in the localization of effects, bearing in mind that the peaks of ef-
fect size in any one sample depend strongly on the noise and any
unmodeled biological variation in the data. A similar situation was
found in Kohannim et al. (2012), where we found significant, diffuse
effects of the autism risk gene, MACROD2, on brain volumes in two
different cohorts, but not in exactly the same locations in the brain.
As such, we did not make a strong a priori hypothesis about the
exact location of the effects, as any clusters in the statistical fields
should not be considered the only places where biological effects
are found, but simply evidence that there is a distributed effect on
the brain. The overall significant associations between the MTHFR
allele and brain volumes, in ADNI and CHS subjects alike, probably
provide evidence that there is a distributed effect of the MTHFR al-
lele on the brain; thereby providing support for considering repli-
cation of the MTHFR associations with brain volumes.
When controlling for the effects of the ApoE4 allele, in addition to
age and sex, there was no effect on the associations of theMTHFR risk
allele and brain structure. ApoE4 risk alleles are associated with tem-
poral lobe volume deficits and ventricular expansion (Hua et al.,
2008a; Schuff et al., 2009), but the profile of these deficits does not
appear to interact with, or underlie, the associations ofMTHFR risk al-
lele. Therefore,MTHFR risk alleles are likely to exert their influence on
brain structure independent of ApoE4.
Folate is essential for the stability and synthesis of myelin basic
protein, which, in turn, is essential for white matter structure in the
central nervous system. It acts as a coenzyme for a large number of
metabolic reactions in the body and affects brain structure indepen-
dent of plasma homocysteine levels. Also, the effects MTHFR variant
on plasma homocysteine levels are pronounced when serum folate
levels are low. Therefore, we adjusted for folate in theMTHFR SNP as-
sociations with brain structure in the CHS study but found that it did
not affect the associations. In the ADNI study – unlike the CHS – folate
levels were not measured in the subjects; so we could not test for
MTHFR associations with brain structure, independent of folate levels
in ADNI subjects. Folate supplementation is known to improve cogni-
tive performance in the elderly with dementia and elevated plasma
homocysteine (Nilsson et al., 2001). We were unable to look into fo-
late supplements as we did not have the necessary data in this im-
aged cohort.
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correlations for the MTHFR C677T risk allele with brain volumes
weakened, suggesting that the MTHFR effect on brain structure may
in part be due to homocysteine elevation induced by the risk allele.
The MTHFR risk allele may also directly affect brain structure inde-
pendent of the homocysteine pathway. The MTHFR risk allele that is
known to increase homocysteine levels has been shown, albeit incon-
sistently, to be associated with AD (Anello et al., 2004; Brunelli et al.,
2001; Mansoori et al., 2011; Prince et al., 2001; Wang et al., 2005),
vascular dementia (Chapman et al., 1998; Pollak et al., 2000), silent
brain infarcts (Kohara et al., 2003) and white matter hyperintensities
(Hong et al., 2009; Kohara et al., 2003). This, by itself, may increase
the MTHFR variant associated risk for brain atrophy through various
mechanisms including plaques and tangles (Vermeer et al., 2007),
in addition to increased homocysteine levels.
Our finding of theMTHFR gene variant associations with brain at-
rophy may have implications for randomized controlled trials of
medications aiming to lower homocysteine levels to resist brain de-
generation. Some clinical trials target the folate pathway specifically,
and advocate taking high doses of B vitamins as a preventative mea-
sure against further brain atrophy (Smith et al., 2010) and cognitive de-
cline (Jager et al., 2011) in subjects with mild cognitive impairment. In
such trials, and in epidemiological studies, it may help to genotype at
thisMTHFR SNP, as these genotypesmay influence homocysteine levels
and the observed pattern of atrophy. Further cross-sectional and pro-
spective studies will be helpful in replicating these findings.
Our study was carried out in a large well-characterized cohort
(ADNI n=359; CHS n=51) with high-quality standardized brain
MRI, and well-validated computational methods to map patterns
and rates of brain atrophy at a local level. We found significant asso-
ciations of the MTHFR SNP with brain volumes in the subjects diag-
nosed with MCI in both ADNI and CHS studies, even though the
replication sample was relatively small (n=51).
The minor allele frequency for the MTHFR SNP varies moderately
across different populations worldwide, and is reported to be 31% in
Western and Central Europeans, 33% in US Chinese, 16% in US Gujara-
ti Indians, 41% in US Mexicans, and 12% in African Americans
(Altshuler et al., 2010). The subjects analyzed in the study were of
Caucasian origin in both the cohorts to avoid spurious results due to
population stratification (Lander and Schork, 1994). As a result, care
must be exercised in generalizing our findings to ethnic groups with
different allele frequencies and possibly different environmental
influences.
Homocysteine levels in the CSF and plasma are highly correlated
(r=0.85) (Selley et al., 2002) but it is difficult to ascertain whether
plasma homocysteine and folate levels correlate between blood and
cerebrospinal fluid, especially when their values are not very high,
as in the subjects studied here. Therefore in addition to elevated ho-
mocysteine, several other mechanisms such as dietary methionine in-
take, toxic habits, and pyridoxal-phosphate levels may contribute
towards the effect of theMTHFR SNP on brain structure. Unfortunate-
ly, these measures were not available to us in the current study.
Conclusions
These brain maps reveal that a commonly carried susceptibility al-
lele for higher homocysteine is also associated with structural brain
volume deficits and with accelerated rates of brain atrophy over
time. As homocysteine is involved in this pathway and in the level
of atrophy, the deficits may be resisted even in MTHFR gene risk al-
lele carriers, at least in principle, via efforts to lower homocysteine
levels. Healthy lifestyle changes such as increasing dietary folate
and supplementation with B vitamins (Blaise et al., 2007; Smith et
al., 2010) in carriers of the MTHFR risk variant may help slow the
rate of atrophy, especially in elderly subjects with mild cognitive
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